Efficacy of tranylcypromine in bipolar depression: A systematic review

Journal of Clinical Psychopharmacology

Volumn 35, Issue 6, 2015, Pages 700-705

  Heijnen, Willemijn T ^a   De Fruyt, Jürgen ^b   Wierdsma, André I ^a   Sienaert, Pascal ^c   Birkenhäger, Tom K ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b General Hospital St Jan   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

bipolar depression; efficacy; systematic review; tranylcypromine

Indexed keywords

IMIPRAMINE; LAMOTRIGINE; PLACEBO; TRANYLCYPROMINE; MONOAMINE OXIDASE INHIBITOR;

ADD ON THERAPY; BIPOLAR DEPRESSION; COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; DEPRESSION ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; EMBASE; EVIDENCE BASED PRACTICE; HUMAN; HYPOMANIA; MEDLINE; MENTAL PATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; BIPOLAR DISORDER; FEMALE; MALE; MIDDLE AGED;

ADULT; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; TRANYLCYPROMINE;

EID: 84947029786     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000409     Document Type: Review

References (35)

1. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530-537.
2. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261-269.
3. De Fruyt J, Demyttenaere K. Bipolar (spectrum) disorder and mood stabilization: standing at the crossroads? Psychother Psychosom. 2007;76:77-88.
4. Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62:1322-1330.
5. Nolen WA, Bloemkolk D. Treatment of bipolar depression, a review of the literature and a suggestion for an algorithm. Neuropsychobiology. 2000;42:11-17.
6. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161:1537-1547.
7. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011;72:156-167.
8. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71:163-174.
9. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. Am J Psychiatry. 2013;170:1249-1262.
10. Van Lieshout RJ, MacQueen GM. Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry. 2010;196:266-273.
11. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry. 2000;48:558-572.
12. Himmelhoch JM, Detre T, Kupfer DJ, et al. Treatment of previously intractable depressions with tranylcypromine and lithium. J NervMentDis. 1972;155:216-220.
13. National Institute for Health and Clinical Excellence Guidance; National Collaborating Centre for Mental Health (UK). Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. Leicester, UK: British Psychological Society; 2006.
14. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1-44.
15. Nolen WA, Kupka RW, Schulte PF, et al. Richtlijn bipolaire stoornissen. Tweede, herziene versie, 2008. Nederlandse vereniging voor psychiatrie. Utrecht: De tijdstroom; 2008.
16. Birkenhäger TK, van den Broek WW, Mulder PG, et al. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry. 2004;65:1505-1510.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare ADM 76-338; 1976:218-222.
18. HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
20. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73:159-171.
21. Nolen WA, Kupka RW, Hellemann G, et al. Tranylcypromine vs lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand. 2007;115:360-365.
22. Raskin A, Schulterbrandt J, Reatig N, et al. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J NervMent Dis. 1969;148:87-98.
23. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148: 910-916.
24. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992;149:195-198.
25. Himmelhoch JM, Fuchs CZ, Symons BJ. A double-blind study of tranylcypromine treatment of major anergic depression. J NervMent Dis. 1982;170:628-634.
26. Mallinger AG, Frank E, Thase ME, et al. Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior? Psychopharmacol Bull. 2009;42:64-74.
27. Ketter TA, Post RM, Parekh PI, et al. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J Clin Psychiatry. 1995;56:471-475.
28. Mitchell PB, Goodwin GM, Johnson GF, et al. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 2008;10: 144-152.
29. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12:185-219.
30. Blom MJ, Nolen WA. red. Protocol gebruik klassieke MAO-remmers. Enspijk: Daleco Pharma, 2009. Available at: http://hulpgids. nl/files/mao- protocol. pdf. Accessed January 21, 2015.
31. Goldberg JF, Thase ME. Monoamine oxidase inhibitors revisited: what you should know. J Clin Psychiatry. 2013;74:189-191.
32. De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2012;26:603-617.
33. AstraZeneca [Internet]. Effectiveness of quetiapine XR versus sertraline in acute depression as add-on therapy to previous mood stabilizer treatment: a pilot study. 2012. Available at: http://www. astrazenacaclinicaltrials. com/Submission/View?id=1406. Accessed May 6, 2015.
34. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20: 226-247.
35. Silverstone T. Moclobemide vs imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand. 2001;104:104-109.